The social stigma attached to urinary incontinence coupled with the side effects of some existing treatments are restraining market expansion. However, the recent launch of new and improved products, coupled with the anticipated launch of more novel offerings will help market participants to grow despite the challenges that exist in the market. Increasing awareness levels and priority given to urinary incontinence by both patients and medical professionals, will be key to widening the patient pool and boosting uptake levels.
New analysis from Frost & Sullivan (pharma.frost.com) European Urinary Incontinence Therapeutics Market, finds that the market was valued at $393.6 million in 2006 and estimates this to reach $967.0 million in 2013.
If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the latest analysis of the European Urinary Incontinence Therapeutics Market, send an email to Radhika Menon Theodore, Corporate Communications, at rmtheodore[.]frost.com with your full name, company name, title, telephone number, email address, city, state and country. We will send you the information through email upon receipt of the above information.
“The urinary incontinence therapeutics market in Europe will experience sustained growth in the coming years,” notes Frost & Sullivan Research Analyst Vaibhav Sarvesh, “Rising awareness allied with the expected launch of improved products will be the major drivers in market expansion.”
Current therapeutic options are primarily geared to treat urge urinary incontinence and have been associated with side effects that nullify are effecting the performance of the drugs. However, recently launched products have a better safety profile and have been well accepted. More products with novel approaches are set to be introduced in the market and boost revenue prospects.
However, the low importance given to the disease by physicians coupled with the limited awareness of this condition will pose significant challenges to market growth. Moreover, the SUI therapeutics market faces stiff competition from alternative treatment options, thereby restraining potential market development.
“Well-established drugs will face very stiff competition from more recently released therapeutics and will show continuous decline in their market share,” adds Mr. Sarvesh. “The expected launch of some novel therapies will further reduce the market share of the older drug therapies, but will benefit the market in general as it will induce more patients to embrace therapeutic treatment for their condition.”
Increasing importance given to urinary incontinence by physicians will be key in augmenting the number of patients adopting therapeutics options. Novel treatments, expected to be launched for the treatment of urinary incontinence, will also positively impact market growth.
“The lack of therapeutic options for SUI will present the most obvious lacunae in this market,” concludes Mr. Sarvesh. “Raising awareness levels about the sole therapeutic option available for SUI will be critical for its success.”
European Urinary Incontinence Therapeutics Market is part of the Pharmaceutical & Biotechnology Subscription, which also includes research in the following markets: European Endometriosis Therapeutics Market, European Blockbusters coming off patent - Opportunities for Generics, and European Osteoarthritis Therapeutics Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.